Person profile

Public information reviewed

Mark C. McKenna

Board role

Director · NewAmsterdam Pharma Co N.V. (NASDAQ: NAMSW)

Board role

Director · Apogee Therapeutics, Inc. (NASDAQ: APGE)

Board role

Director · Perceptive Capital Solutions Corp (NASDAQ: FRNM)

NewAmsterdam Pharma Co N.V. (NASDAQ: NAMSW)

Director · Current mandate

Director · Executive
FollowSave PDF
More
Reports & analysis (Check report directory)Alpha Eval
Evidence records
10
Profile ownership
Not yet claimed
Record reviewed
Sep 6, 2026
View evidence

Structured intelligence coverage

Structured records are temporarily unavailable. The published profile and its source ledger remain accessible.

Identity checks do not refresh the age of governance evidence. Open a record for its source date and review state.

Profile

Identity, professional record and current appointments.

Overview

Professional record at a glance

A concise summary of information supported by the cited public sources. Missing information is treated as unknown, not as a negative finding.

Current roles
33 current organizations shown on this profile
Board positions
33 supported by public sources, 0 supplied by the profile owner
Committee roles
2Roles supported by the sources cited on this profile
Qualifications
Not establishedNo qualification is currently confirmed by the cited sources

Professional narrative

About

Extensive biopharmaceutical executive experience including President and CEO of Prometheus Biosciences and President of Salix Pharmaceuticals. Currently serves as CEO of Mirador Therapeutics and Chair of Apogee Therapeutics.

Sources are shown with the information they support.

Current roles

Appointments & responsibilities

Board appointments

Governance

Board appointments, committee responsibilities and disclosed relationships.

Committee appointments across companies · Temporarily unavailable

Structured records for this section are unavailable. This does not establish that no records exist. Published profile sources remain in Evidence & History.

Board and advisory record

Board service

Sources are shown with each role, education record, or credential.

Director

NewAmsterdam Pharma Co N.V.

2024-01-01 · current

Confirmed by public sourceView source

Director

Apogee Therapeutics, Inc.

2023-01-01 · current

Confirmed by public sourceView source

Director

Perceptive Capital Solutions Corp

Current · start date not disclosed

Confirmed by public sourceView source

Connections

Explore the roles, education and affiliations published in this record.

Apogee Therapeutics, Inc.

Open Apogee Therapeutics, Inc. profile →

Director at Apogee Therapeutics, Inc.

2023-01-01 → End not stated

current · source reported

Observed: 2026-09-25

Apogee Therapeutic…Apogee Therapeutics, Inc.NewAmsterdam Pharm…NewAmsterdam Pharma Co N.V.Perceptive Capital…Perceptive Capital Solutions CorpMark C. McKenna

Dashed lines mark past roles. Select a connection to see its dates and sources.

Relationship map

Connected through the public record

Direct relationships from verified facts and published résumé records. Private connections are excluded.

Direct public links only

Only published affiliations are shown here. Private relationships require authorized access.

Experience

Career history, education, credentials and public contributions.

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · Sec Def 14aPublic profile sourceSupports Director at Perceptive Capital Solutions Corp (NASDAQ: FRNM).Open sourceSource 2 · Sec FilingHLXC 10-K executive officersSupports Executive company, Executive title.Open sourceSource 3 · Sec FilingPCSC 10-K executive officersSupports AI and ML experience, Cybersecurity experience, Executive company, Executive title, Other Company Role, Technology background.Open sourceSource 4 · Sec FilingNAMS DEF 14A director slateSupports AI and ML experience, Board role, Committee assignments, Executive company, Executive title, Cybersecurity experience, Technology background.Open sourceSource 5 · Sec FilingAPGE DEF 14A director slateSupports Board role, Committee assignments.Open source

Basis

Identifiers, sources, dates and record limitations.

Identifiers

Alpha ID
alpha:person:mark-c-mckenna
Record version
public-0

Published evidence records

10 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. Open source

    sec def 14a · Source published: May 14, 2026 · Retrieved: Sep 6, 2026

    Supports 1 claim
    • Professional Role: Director at Perceptive Capital Solutions Corp · Claim reviewed: Sep 6, 2026

  2. HLXC 10-K executive officers

    sec filing · Source published: Mar 31, 2026 · Retrieved: May 16, 2026

    Supports 2 claims
    • Executive company: Executive at Helix Acquisition Corp. III · Claim reviewed: May 16, 2026
    • Executive title: Executive title: Director · Claim reviewed: May 16, 2026

  3. PCSC 10-K executive officers

    sec filing · Source published: Mar 12, 2026 · Retrieved: May 16, 2026

    Supports 6 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Executive company: Executive at Perceptive Capital Solutions Corp · Claim reviewed: May 16, 2026
    • Executive title: Executive title: Director · Claim reviewed: May 16, 2026
    • Other Company Role: Mark C. McKenna is also linked to Mirador Therapeutics, Inc. as Founder, Chief Executive Officer and Chairman. · Claim reviewed: May 16, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026

  4. NAMS DEF 14A director slate

    sec filing · Source published: May 8, 2025 · Retrieved: May 16, 2026

    Supports 7 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Board role: Board role: Vice Chair · Claim reviewed: May 16, 2026
    • Committee assignments: No committee assignment disclosed in the cited filing · Claim reviewed: May 16, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Executive company: Executive at Mirador Therapeutics · Claim reviewed: May 16, 2026
    • Executive title: Executive title: Founder, Chairman and Chief Executive Officer · Claim reviewed: May 16, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026

  5. Open source

    sec proxy · Source published: May 8, 2025 · Retrieved: Apr 28, 2026

    Supports 1 claim
    • Professional Role: Director at NewAmsterdam Pharma Co N.V. · Claim reviewed: Sep 6, 2026

  6. APGE DEF 14A director slate

    sec filing · Source published: Apr 29, 2025 · Retrieved: May 15, 2026

    Supports 2 claims
    • Board role: Board role: Chair · Claim reviewed: May 15, 2026
    • Committee assignments: Committee assignments: Compensation, Nominating/Governance · Claim reviewed: May 15, 2026

  7. Open source

    sec proxy · Source published: Apr 29, 2025 · Retrieved: Apr 24, 2026

    Supports 1 claim
    • Professional Role: Director at Apogee Therapeutics, Inc. · Claim reviewed: Sep 6, 2026

  8. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of NewAmsterdam Pharma Co N.V. · Claim reviewed: Sep 6, 2026

  9. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Apogee Therapeutics, Inc. · Claim reviewed: Sep 6, 2026

  10. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Perceptive Capital Solutions Corp · Claim reviewed: Sep 6, 2026

Sources

Sources and published information

Each item links to the public source used to support it. When sources disagree, the item is clearly marked for review.

AI and ML experience · CorroboratedAI and ML experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Board membership · Source reportedServes on the board of Apogee Therapeutics, Inc.1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board membership · Source reportedServes on the board of NewAmsterdam Pharma Co N.V.1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board membership · Source reportedServes on the board of Perceptive Capital Solutions Corp1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board role · Source reportedBoard role: Chair1 source
Verification
Source reported
Confidence
92%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Board role · Source reportedBoard role: Vice Chair1 source
Verification
Source reported
Confidence
92%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Committee assignments · Source reportedNo committee assignment disclosed in the cited filing1 source
Verification
Source reported
Confidence
88%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Committee assignments · Source reportedCommittee assignments: Compensation, Nominating/Governance1 source
Verification
Source reported
Confidence
88%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Cybersecurity experience · CorroboratedCybersecurity experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive company · Source reportedExecutive at Helix Acquisition Corp. III1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive company · Source reportedExecutive at Mirador Therapeutics1 source
Verification
Source reported
Confidence
85%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive company · Source reportedExecutive at Perceptive Capital Solutions Corp1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive title · CorroboratedExecutive title: DirectorSupported by 2 public records2 sources
Verification
Corroborated
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive title · Source reportedExecutive title: Founder, Chairman and Chief Executive Officer1 source
Verification
Source reported
Confidence
85%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Other Company Role · Source reportedMark C. McKenna is also linked to Mirador Therapeutics, Inc. as Founder, Chief Executive Officer and Chairman.1 source
Verification
Source reported
Confidence
70%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Technology background · CorroboratedTechnology background: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

View all sources10 records
  1. https://www.sec.gov/Archives/edgar/data/2017526/000114036126021304/ny20072405x2_def14a.htm

    Sec Def 14a · Tier not stated · Reviewed Sep 6, 2026

    Supports: Director at Perceptive Capital Solutions Corp (NASDAQ: FRNM)

  2. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: Executive company · Executive title

  3. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: AI and ML experience · Cybersecurity experience · Executive company · Executive title · Other Company Role · Technology background

  4. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: AI and ML experience · Board role · Committee assignments · Executive company · Executive title · Cybersecurity experience · Technology background

  5. https://www.sec.gov/Archives/edgar/data/1936258/000119312525115995/d904380ddef14a.htm

    Sec Proxy · Tier not stated · Reviewed Apr 28, 2026

    Supports: Director at NewAmsterdam Pharma Co N.V. (NASDAQ: NAMSW)

  6. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

    Supports: Board role · Committee assignments

  7. https://www.sec.gov/Archives/edgar/data/1974640/000095017025060147/apge-20250429.htm

    Sec Proxy · Tier not stated · Reviewed Apr 24, 2026

    Supports: Director at Apogee Therapeutics, Inc. (NASDAQ: APGE)

  8. https://www.sec.gov/Archives/edgar/data/1936258/000119312525115995/d904380ddef14a.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership

  9. https://www.sec.gov/Archives/edgar/data/1974640/000095017025060147/apge-20250429.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership

  10. https://www.sec.gov/Archives/edgar/data/2017526/000114036126021304/ny20072405x2_def14a.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership